Drug
Dsg3 Caart
Dsg3 Caart: highest development phase Phase 1/2, developed by Cabaletta Bio. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Cabaletta Bio
Trials
| Drug | Phase | Indication |
|---|---|---|
| DSG3-CAART NCT04422912 | Phase 1/2 | Pemphigus Vulgaris |
Latest
No recent events.
Follow Dsg3 Caart on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.